Scientific Reports · 2019 · 21 citations · 70 references
MedicineCancer BiologyOncologyAntibody EngineeringChemotherapyDna RepairAntibody Fragment EngineeringCell-penetrating PeptidesDna Damage SignalingRecombination ProteinsTargeted Cancer TherapyTherapeutic Protein EngineeringDna Damage Response InhibitorsDna Repair MechanismsFab Antibody FragmentsHomologous Recombination RepairRad51 ProteinRad51 RegulationRad51-mediated RepairRecombinant Antibody Therapeutics
Abstract DNA damaging chemotherapies are successful in cancer therapy, however, the damage can be reversed by DNA repair mechanisms that may be up-regulated in cancer cells. We hypothesized that inhibiting RAD51, a protein involved in homologous recombination DNA repair, would block DNA repair and restore the effectiveness of DNA damaging chemotherapy. We used phage-display to generate a novel synthetic antibody fragment that bound human RAD51 with high affinity (K D = 8.1 nM) and inhibited RAD51 ssDNA binding in vitro . As RAD51 is an intracellular target, we created a corresponding intrabody fragment that caused a strong growth inhibitory phenotype on human cells in culture. We then used a novel cell-penetrating peptide “iPTD” fusion to generate a therapeutically relevant antibody fragment that effectively entered living cells and enhanced the cell-killing effect of a DNA alkylating agent. The iPTD may be similarly useful as a cell-penetrating peptide for other antibody fragments and open the door to numerous intracellular targets previously off-limits in living cells.
70
Enzymatic assembly of DNA molecules up to several hundred kilobases
Daniel G. Gibson, Lei Young, Ray-Yuan Chuang et al. · Nature Methods · 2009 · 10.9K citations
James S. Huston, Dennis J. Levinson, M Mudgett-Hunter et al. · Proceedings of the National Academy of Sciences · 1988 · 1.6K citations · Full text